Phosphorylated insulin-like growth factor-I/insulin receptor is present in all breast cancer subtypes and is related to poor survival

Cancer Research

Volumn 68, Issue 24, 2008, Pages 10238-10246

  Law, Jennifer H ^a   Habibi, Golareh ^a   Hu, Kaiji ^a   Masoudi, Hamid ^a   Wang, Michelle Y C ^a   Stratford, Anna L ^a   Park, Eugene ^a   Gee, Julia M W ^b   Finlay, Pauline ^b   Jones, Helen E ^b   Nicholson, Robert I ^b   Carboni, Joan ^c   Gottardis, Marco ^c   Pollak, Michael ^d   Dunn, Sandra E ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c BRISTOL MYERS SQUIBB   (United States)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BMS 536924; INSULIN RECEPTOR; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER INVASION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG RESISTANCE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PHOSPHORYLATION; RECEPTOR UPREGULATION;

BENZIMIDAZOLES; BREAST NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; HUMANS; INSULIN-LIKE GROWTH FACTOR I; PHOSPHORYLATION; PYRIDONES; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN;

EID: 57749089652     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-2755     Document Type: Article

References (44)

1. Kucab JE, Dunn SE. Role of IGF-1R in mediating breast cancer invasion and metastasis. Breast Dis 2003;17:41-7.
2. Dupont J, Le Roith D. Insulin-like growth factor 1 and oestradiol promote cell proliferation of MCF-7 breast cancer cells: new insights into their synergistic effects. Mol Pathol 2001;54:149-54.
3. Carboni JM, Lee AV, Hadsell DL, et al. Tumor development by transgenic expression of a constitutively active insulin-like growth factor Ireceptor. Cancer Res 2005;65:3781-7.
4. Kim HJ, Litzenburger BC, Cui X, et al. Constitutively active type I insulin-like growth factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelial-to-mesenchymal transition mediated by NF-κB and snail. Mol Cell Biol 2007;27:3165-75.
5. Arteaga CL, Kitten LJ, Coronado EB, et al. Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest 1989;84:1418-23.
6. Jones RA, Campbell CI, Gunther EJ, et al. Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation. Oncogene 2007;26:1636-44.
7. Zhang H, Yee D. The therapeutic potential of agents targeting the type I insulin-like growth factor receptor. Expert Opin Investig Drugs 2004;13:1569-77.
8. Tao Y, Pinzi V, Bourhis J, Deutsch E. Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway-therapeutic perspectives in cancer. Nat Clin Pract Oncol 2007;4:591-602.
9. Ryan PD, Goss PE. The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer. Oncologist 2008;13:16-24.
10. Wittman M, Carboni J, Attar R, et al. Discovery of a (1H-benzoimidazol-2- yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity. J Med Chem 2005;48:5639-43.
11. Dupont J, Dunn SE, Barrett JC, LeRoith D. Microarray analysis and identification of novel molecules involved in insulin-like growth factor-1 receptor signaling and gene expression. Recent Prog Horm Res 2003;58:325-42.
12. Hartog H, Wesseling J, Boezen HM, van der Graaf WT. The insulin-like growth factor 1 receptor in cancer: old focus, new future. Eur J Cancer 2007;43:1895-904.
13. Frasca F, Pandini G, Sciacca L, et al. The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem 2008;114:23-37.
14. Hofmann F, Garcia-Echeverria C. Blocking the insulin-like growth factor-Ireceptor as a strategy for targeting cancer. Drug Discov Today 2005;10:1041-7.
15. Haluska P, Carboni JM, Loegering DA, et al. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. Cancer Res 2006;66:362-71.
16. Jones HE, Goddard L, Gee JM, et al. Insulin-like growth factor-Ire ceptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 2004;11:793-814.
17. Knowlden JM, Hutcheson IR, Barrow D, Gee JM, Nicholson RI. Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor. Endocrinology 2005;146:4609-18.
18. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-Ireceptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001;93:1852-7.
19. Guix M, Faber AC, Wang SE, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 2008;118:2609-19.
20. Harris LN, You F, Schnitt SJ, et al. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res 2007;13:1198-207.
21. Knowlden JM, Jones HE, Barrow D, Gee JM, Nicholson RI, Hutcheson IR. Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance. Breast Cancer Res Treat 2008;111:79-91.
22. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
23. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100:8418-23.
24. van 't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
25. Nielsen TO, Andrews HN, Cheang M, et al. Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention with 17-allylamino geldanamycin. Cancer Res 2004;64:286-91.
26. Gee JM, Robertson JF, Gutteridge E, et al. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer 2005;12 Suppl 1:S99-111.
27. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004;4:505-18.
28. Garber K. IGF-1: old growth factor shines as new drug target. J Natl Cancer Inst 2005;97:790-2.
29. Makretsov N, Huntsman D, Nielsen T, et al. Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma. Clin Cancer Res 2004;10:6143-51.
30. Sutherland BW, Kucab J, Wu J, et al. Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene 2005;24:4281-92.
31. Kucab JE, Lee C, Chen CS, et al. Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. Breast Cancer Res 2005;7:R796-807.
32. Sell C, Dumenil G, Deveaud C, et al. Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol Cell Biol 1994;14:3604-12.
33. Stratford AL, Habibi G, Astanehe A, et al. Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy. Breast Cancer Res 2007;9:R61.
34. Berquin IM, Pang B, Dzuibinski ML, et al. Y-box binding protein 1 confers EGF independence to human mammary epithelial cells. Oncogene 2005;21:1-10.
35. To K, Zhao Y, Jiang H, et al. The phosphoinositide-dependent kinase-1 inhibitor, 2-amino-n-[4-5-(2-phenanthrenyl)-3-(trifluoromethyl)-1h-pyrazol-1-yl] -acetaminde (OSU03012) prevents Y-box binding protein-1 from inducing epidermal growth factor receptor. Mol Pharmacol 2007;72 no 3:641-52.
36. Wu J, Lee C, Yokom D, et al. Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2. Cancer Res 2006;66:4872-9.
37. Provenzano PP, Eliceiri KW, Campbell JM, Inman DR, White JG, Keely PJ. Collagen reorganization at the tumor-stromal interface facilitates local invasion. BMC Med 2006;4:38.
38. Iwenofu OH, Lackman RD, Staddon AP, Goodwin DG, Haupt HM, Brooks JS. Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy. Mod Pathol 2008;21:231-7.
39. Carriere A, Ray H, Blenis J, Roux PP. The RSK factors of activating the Ras/MAPK signaling cascade. Front Biosci 2008;13:4258-75.
40. Frodin M, Gammeltoft S. Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction. Mol Cell Endocrinol 1999;151:65-77.
41. Haluska P, Carboni JM, Teneyck C, et al. HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Mol Cancer Ther 2008;7:2589-98.
42. Smith JA, Poteet-Smith CE, Xu Y, Errington TM, Hecht SM, Lannigan DA. Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation. Cancer Res 2005;65:1027-34.
43. Papa V, Costantino A, Belfiore A. Insulin receptor what role in breast cancer? Trends Endocrinol Metab 1997;8:306-12.
44. Chakraborty AK, Liang K, DiGiovanna MP. Co-targeting insulin-like growth factor I receptor and HER2: dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer. Cancer Res 2008;68:1538-45.